← Back to Clinical Trials
Recruiting NCT07316478

NCT07316478 Stress Management and Mindfulness Intervention for Patients With Sickle Cell Disease

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT07316478
Status Recruiting
Phase
Sponsor University of Pennsylvania
Condition Sickle Cell Disease
Study Type INTERVENTIONAL
Enrollment 50 participants
Start Date 2026-01-15
Primary Completion 2026-12-30

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age N/A
Study Type INTERVENTIONAL
Interventions
Stress Management and Mindfulness Intervention for Patients with Sickle Cell Disease

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 50 participants in total. It began in 2026-01-15 with a primary completion date of 2026-12-30.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

The purpose of this research is to determine whether a new stress management and mindfulness program can improve quality of life in individuals with sickle cell disease. The program is based on a number of empirically supported treatments including techniques from cognitive-behavioral therapy like overcoming motivational barriers to self-care, learning to see things as accurately as possible, practicing assertive communication, relaxation exercises like deep slow breathing, mindfulness meditation, and other stress management strategies.

Eligibility Criteria

Inclusion Criteria: * 18 years of age or older. * Diagnosed with sickle cell disease. * Live within 90 minutes of Philadelphia Exclusion Criteria: \- Severe depression or suicidality

Contact & Investigator

Central Contact

Melissa G Hunt, PhD

✉ mhunt@psych.upenn.edu

📞 610-529-8055

Principal Investigator

Melissa G Hunt, PhD

PRINCIPAL INVESTIGATOR

University of Pennsylvania

Frequently Asked Questions

Who can join the NCT07316478 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, studying Sickle Cell Disease. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT07316478 currently recruiting?

Yes, NCT07316478 is actively recruiting participants. Contact the research team at mhunt@psych.upenn.edu for enrollment information.

Where is the NCT07316478 trial being conducted?

This trial is being conducted at Philadelphia, United States.

Who is sponsoring the NCT07316478 clinical trial?

NCT07316478 is sponsored by University of Pennsylvania. The principal investigator is Melissa G Hunt, PhD at University of Pennsylvania. The trial plans to enroll 50 participants.

Related Trials

Related Intelligence Guides

In-depth guides covering this condition's trials, eligibility, and what to expect.

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: September 2026  ·  Data Methodology